Quantum BioPharma Ltd
NASDAQ:QNTM
Net Margin
Quantum BioPharma Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CA |
Q
|
Quantum BioPharma Ltd
CNSX:QNTM
|
84m CAD | N/A | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
723.1B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
404.4B USD |
25%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
206.4B CHF |
14%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.5T DKK |
35%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
173B GBP |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
183.4B CHF |
25%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
207.9B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
138.1B USD |
13%
|
Quantum BioPharma Ltd
Glance View
Quantum BioPharma Ltd is a CA-based company operating in Pharmaceuticals industry. The company is headquartered in Toronto, Ontario. The company went IPO on 2018-05-29. Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The firm is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Quantum BioPharma Ltd's most recent financial statements, the company has Net Margin of 0%.
You don't have any saved screeners yet